Tirzepatide research.

Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide engineered as a single-molecule dual agonist at the GIP and GLP-1 receptors. Since its first pharmacological characterisation by Coskun and colleagues in 2018, it has become one of the most extensively investigated incretin-class peptides in modern metabolic research.

The research landscape around tirzepatide spans four broad strata: (i) in-vitro receptor pharmacology and signalling-bias studies, (ii) preclinical rodent and non-human primate metabolic models, (iii) the Phase 3 SURPASS clinical trial programme in type-2 diabetes research populations, and (iv) the Phase 3 SURMOUNT programme in obesity research populations. This page provides the laboratory-oriented overview — receptor-level detail is owned by the Tirzepatide mechanism of action page, and a dedicated clinical-trial deep-dive is scheduled for future publication.

Tirzepatide emerged from an Eli Lilly discovery programme aimed at unifying GIP and GLP-1 agonism within a single, once-weekly peptide backbone. The molecule combines a modified GIP scaffold with a C20 fatty diacid moiety that supports albumin binding and extended pharmacokinetics. The design rationale and initial pharmacology were reported by Coskun et al. (2018), with subsequent signalling-bias characterisation published by Willard et al. (2020).

Early clinical pharmacology (Urva et al., 2020) established the pharmacokinetic profile supporting once-weekly dosing in trials, which underpinned the SURPASS and SURMOUNT Phase 3 programmes. For a fuller narrative on the compound's origins, see What is Tirzepatide?

Within in-vitro research, tirzepatide is commonly used as the reference dual agonist for GIP + GLP-1 receptor pharmacology. Typical applications include:

• Comparative receptor-binding and competition assays against single GLP-1 agonists (semaglutide) and triple agonists (retatrutide).
• Functional cAMP accumulation assays in GIP-R- and GLP-1-R-expressing cell lines.
• β-arrestin recruitment and signalling-bias profiling.
• Structure–activity relationship studies of fatty-acid-conjugated incretin analogues.
• Stability and formulation reference studies for long-acting peptide backbones.

Reproducibility across all of the above depends on a well-characterised research-grade peptide with a traceable batch-specific COA — a requirement documented in our laboratory quality framework.

The tirzepatide literature has grown rapidly since 2018 and now spans hundreds of peer-reviewed publications. The most widely cited foundational papers are summarised in the Scientific References section below and include:

• Coskun et al., 2018 (Molecular Metabolism): initial pharmacological characterisation as a balanced dual GIP / GLP-1 agonist.
• Willard et al., 2020 (JCI Insight): imbalanced and biased dual agonism, with GLP-1R signalling bias.
• Urva et al., 2020 (Clinical Pharmacokinetics): pharmacokinetic profile supporting once-weekly dosing.
• SURPASS-2 (Frías et al., 2021, NEJM): tirzepatide vs semaglutide in T2D research.
• SURMOUNT-1 (Jastreboff et al., 2022, NEJM): tirzepatide in obesity research.

SURPASS is the Eli Lilly Phase 3 clinical trial programme that evaluated tirzepatide in type-2 diabetes research populations. The programme is referenced across the pharmacology literature as the primary source of comparative data for the dual GIP / GLP-1 mechanism against established GLP-1 monotherapy and basal insulin comparators.

For laboratory-supply purposes SURPASS is relevant only as the citation framework for the dual-agonist class; a dedicated SURPASS deep-dive is planned as a separate clinical-trial page and is not duplicated here.

SURMOUNT is the Eli Lilly Phase 3 clinical trial programme that evaluated tirzepatide in body-weight and obesity research populations. As with SURPASS, it is referenced here purely as the citation backbone for the dual-incretin obesity-research literature; the receptor-level mechanism is documented on the Tirzepatide mechanism of action page.

Tirzepatide occupies a distinctive position within incretin pharmacology because it is the first clinically validated dual GIP / GLP-1 agonist. That places it as the reference midpoint between single GLP-1 agonists and triple agonists such as retatrutide, and gives it a defined role in structure-activity, signalling-bias and comparative-potency studies.

• Reference dual agonist for GIP + GLP-1 receptor pharmacology.
• Comparator anchor across single, dual and triple incretin agonists.
• Model peptide for signalling-bias and receptor-trafficking studies.
• Reproducibility benchmark for long-acting fatty-acid-conjugated GLP-1 analogues.

BuyRetaUK releases tirzepatide against the peptide-specific quality attributes described in USP General Chapter <1503>. No vial enters inventory without a formal release specification and a batch-specific Certificate of Analysis. Full detail of our supplier qualification, retained-sample and stability policies is published on the laboratory quality page — this section summarises only the essentials relevant to research use.

• Purity: ≥99% by HPLC-UV area-percent.
• Identity: Mass spectrometry confirmation against theoretical monoisotopic mass.
• Appearance: White to off-white lyophilised cake or powder.
• Traceability: Vial batch number matches the published COA exactly.

Every research-grade tirzepatide batch passes independent HPLC-UV purity confirmation, mass-spec identity verification and visual appearance inspection before release. Batch-specific documentation is published in the public verification library so any laboratory can cross-reference the vial in front of them. For a deeper commercial framing, see the Tirzepatide UK hub.

A Certificate of Analysis (COA) is the primary quality record for a peptide batch. For tirzepatide it summarises compound identity, batch number, manufacture date, purity method and result, mass-spec identity confirmation, appearance, and where determined endotoxin and moisture data.

See the full Certificate of Analysis guide for a section-by-section walkthrough, or open the verification library to cross-reference a specific batch.

Lyophilised tirzepatide vials are stored at 2–8 °C, protected from light. Working stocks reconstituted with bacteriostatic water are held refrigerated and used within 30 days, avoiding repeated freeze-thaw cycles. Full handling detail lives on the dedicated Tirzepatide storage page — kept concise here to avoid duplication.

Use the reconstitution calculator to convert vial strength and target concentration into a diluent volume.